Search

Search Constraints

You searched for: Author/Creator Zhang, N.

Search Results

2. 165P Efficacy and safety of tislelizumab (TIS) plus lenvatinib (LEN) as first-line treatment in patients (pts) with unresectable hepatocellular carcinoma (uHCC): A single-arm, multicenter, phase II trial. (December 2022)